APSR2026-1079

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-029
P71
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1245554-46904-PRESENT_APSR26 Poster_Final Draft_10.30_436446.pdf
Format: PDF Only
09. Asthma
12

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Li Yu * Tongji Hospital, School of Medicine, Tongji University Department of Pulmonary and Critical Care Medicine Shanghai China
Jian He - Anning First People's Hospital Affiliated to Kunming University of Science and Technology Department of Pulmonary and Critical Care Medicine Kunming China
Yuewen Jiang - Qiyang People's Hospital Department of Pulmonary and Critical Care Medicine Yongzhou China
Gang Wang - West China Hospital of Sichuan University Department of Pulmonary and Critical Care Medicine Chengdu China
Xin Feng - Nanbu People’s Hospital Department of Pulmonary and Critical Care Medicine Nanchong China
Lixiu Chen - Zhangjiagang First People’s Hospital Department of Pulmonary and Critical Care Medicine Zhangjiagang China
Kewu Huang - Beijing Chao-Yang Hospital, Capital Medical University Department of Pulmonary and Critical Care Medicine Beijing China
Haiyan Wu - The First People's Hospital of Xiaoshan District Department of Pulmonary and Critical Care Medicine Hangzhou China
Li Zhen - Dingzhou People's Hospital Department of Pulmonary and Critical Care Medicine Dingzhou China
Jie Cao - Tianjin Medical University General Hospital Department of Pulmonary and Critical Care Medicine Tianjin China
Zuoyan Li - Liaoning Province Health Industry Group Iron Coal General Hospital Department of Pulmonary and Critical Care Medicine Tieling China
Zhongmin Qiu - Tongji Hospital, School of Medicine, Tongji University Department of Pulmonary and Critical Care Medicine Shanghai China
 
 
 
Presenting Author Details
Li
Yu
96778@tongji.edu.cn
+8613816699078
51-60
China
Original Research
Disease control status and treatment patterns in Chinese patients with uncontrolled asthma treated with low- to medium-dose ICS: a post-hoc analysis of the PRESENT study
Maximum 25 words
Abstract Content
PRESENT evaluated the clinical profiles of Chinese patients with moderate-to-severe asthma. This post-hoc analysis characterised disease control and treatment patterns in patients with uncontrolled asthma on low-/medium-dose ICS.
PRESENT (NCT06422663) is a prospective, observational, multicentre study across 35 hospitals in China. Eligible patients were aged ≥12 years with moderate-to-severe asthma (receiving GINA Step 3-5 treatment). This post-hoc analysis evaluated patients with uncontrolled asthma receiving low-/medium-dose ICS at baseline (Week 0), stratified by baseline ICS dosage. Uncontrolled asthma was defined as ACT score ≤19, frequent exacerbations (≥2/year) requiring oral corticosteroid for ≥3 days, or ≥1 serious exacerbation requiring hospitalisation or urgent care within 24 hours. Severe asthma was defined by CN 2024 guideline as medium/high dose ICS uncontrolled asthma.
Overall asthma control improved from 46.2% at baseline to 69.1% at Week 24. However, substantial burden remained among patients uncontrolled on medium/high-dose ICS. Among patients uncontrolled on medium-dose ICS at baseline, 44.5% remained uncontrolled at Week 24 despite medium/high-dose. In contrast, among those uncontrolled on low-dose ICS at baseline, 29.5% remained uncontrolled and 8.0% progressed to severe asthma at Week 24. Management also appeared suboptimal: no clear treatment-escalation trend was observed, high-dose ICS use in uncontrolled patients did not increase (7.2% at baseline vs 6.4% at Week 24), eosinophilic phenotype remained unknown in 75.5% and 76.8% of patients at Weeks 12 and 24, respectively, and biologic use remained low.
Severe asthma carry a substantial disease burden, likely greater than that of patients in moderate asthma, while current real-world management remains inadequate. These findings highlight potential under-recognition of severe disease and delayed treatment intensification. Earlier identification and more proactive treatment strategies, including transitioning to biologics, may improve asthma control.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
The authors would like to thank all researchers and patients involved in the study across all research centers. The authors acknowledge Costello Medical for medical writing and editorial assistance, funded by AstraZeneca China, which were in accordance with the Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research.
291